CENTREXION THERAPEUTICS CORP

CNTX NASDAQ
0.0000
0.0000
0.00%
停牌
开盘
--
昨收
--
最高
--
最低
--
成交量
--
成交均量(3M)
--
52周最高
--
52周最低
--
换手率
0%
市值
0
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供CENTREXION THERAPEUTICS CORP CNTX股票价格,CENTREXION THERAPEUTICS CORP股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.
展开 >

最近浏览

名称
价格
涨跌幅